Literature DB >> 26897064

Invasive Aspergillosis: Current Strategies for Diagnosis and Management.

Jose Cadena1, George R Thompson2, Thomas F Patterson3.   

Abstract

Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged. Published by Elsevier Inc.

Entities:  

Keywords:  Aspergilloma; Aspergillosis; Chronic cavitary aspergillosis; Invasive pulmonary aspergillosis; Resistance

Mesh:

Substances:

Year:  2016        PMID: 26897064     DOI: 10.1016/j.idc.2015.10.015

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  32 in total

1.  Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts.

Authors:  Saira Ajmal; Maryam Mahmood; Omar Abu Saleh; Jenifer Larson; M Rizwan Sohail
Journal:  Infection       Date:  2018-04-07       Impact factor: 3.553

2.  Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects.

Authors:  Laura L Kovanda; Sean M Sullivan; Larry R Smith; Amit V Desai; Pete L Bonate; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host complement proteins.

Authors:  Rajashri Shende; Sarah Sze Wah Wong; Srikanth Rapole; Rémi Beau; Oumaima Ibrahim-Granet; Michel Monod; Karl-Heinz Gührs; Jayanta Kumar Pal; Jean-Paul Latgé; Taruna Madan; Vishukumar Aimanianda; Arvind Sahu
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

Review 4.  Combinatorial strategies for combating invasive fungal infections.

Authors:  Michaela Spitzer; Nicole Robbins; Gerard D Wright
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

Review 5.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

6.  Tracheoesophageal fistula induced by invasive pulmonary aspergillosis.

Authors:  Yuetian Yu; Cheng Zhu; Xiaozhe Qian; Yuan Gao
Journal:  Ann Transl Med       Date:  2016-09

Review 7.  Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.

Authors:  Alisha Y Young; Miguel M Leiva Juarez; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-05-31       Impact factor: 2.878

8.  Effects of Itraconazole and Micafungin on Aspergillus fumigatus Biofilms.

Authors:  Musang Liu; Hailin Zheng; Rong Zeng; Guanzhao Liang; Nan Zheng; Weida Liu
Journal:  Mycopathologia       Date:  2021-05-06       Impact factor: 2.574

Review 9.  Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach.

Authors:  S Moura; L Cerqueira; A Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-13       Impact factor: 3.267

10.  A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism.

Authors:  Paris Laskaris; Rocío Vicentefranqueira; Olivier Helynck; Grégory Jouvion; José Antonio Calera; Laurence du Merle; Franck Suzenet; Frédéric Buron; Rodolphe Alves de Sousa; Daniel Mansuy; Jean-Marc Cavaillon; Jean-Paul Latgé; Hélène Munier-Lehmann; Oumaima Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.